Literature DB >> 2506222

Quantitative western immunoblotting analysis in survey of human immunodeficiency virus-seropositive patients.

D G Schiavini1, J M Puel, S A Averous, J A Bazex.   

Abstract

Identifying criteria for the early prediction of progression to acquired immunodeficiency syndrome in asymptomatic human immunodeficiency virus-seropositive patients have become necessary in order to widen the indications for antiviral treatment by azidothymidine and to increase its efficiency. With this aim in mind, we studied a cohort of seropositive homosexual men in the southwest region of France (Midi-Pyrénées). Of all the factors analyzed, the decline in p24 antibodies, assayed by second-generation enzyme-linked immunosorbent assay, was found to be the most reliable. On the basis of the work of Blomberg and Schmidt, we developed a quantitative approach to Western blotting (immunoblotting) for use in the follow-up of human immunodeficiency virus-infected patients. Our technique of quantitative Western blotting is unique because it uses a densitometric reading which, through a computerized system, gives a curve allowing the exact quantification of each stained Western blotting band. The results are expressed as integrals. This technique confirms the decrease in p24 and p17 antibodies as the criterion giving the earliest prediction of the progression to acquired immunodeficiency syndrome.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2506222      PMCID: PMC267739          DOI: 10.1128/jcm.27.9.2062-2066.1989

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  30 in total

1.  From persistent generalised lymphadenopathy to AIDS: who will progress?

Authors:  C A Carne; I V Weller; C Loveday; M W Adler
Journal:  Br Med J (Clin Res Ed)       Date:  1987-04-04

2.  Densitometric analysis of Western blot (immunoblot) assays for human immunodeficiency virus antibodies and correlation with clinical status.

Authors:  G Schmidt; K Amiraian; H Frey; R W Stevens; D S Berns
Journal:  J Clin Microbiol       Date:  1987-10       Impact factor: 5.948

3.  Is presence of interferon predictive for AIDS?

Authors:  E Buimovici-Klein; M Lange; R J Klein; L Z Cooper; M H Grieco
Journal:  Lancet       Date:  1983-08-06       Impact factor: 79.321

4.  Wernicke's encephalopathy in AIDS patient treated with zidovudine.

Authors:  D G Davtyan; H V Vinters
Journal:  Lancet       Date:  1987-04-18       Impact factor: 79.321

Review 5.  Immunology of human immunodeficiency virus infection and the acquired immunodeficiency syndrome. An update.

Authors:  M Seligmann; A J Pinching; F S Rosen; J L Fahey; R M Khaitov; D Klatzmann; S Koenig; N Luo; J Ngu; G Riethmüller
Journal:  Ann Intern Med       Date:  1987-08       Impact factor: 25.391

6.  Azidothymidine associated with bone marrow failure in the acquired immunodeficiency syndrome (AIDS).

Authors:  P S Gill; M Rarick; R K Brynes; D Causey; C Loureiro; A M Levine
Journal:  Ann Intern Med       Date:  1987-10       Impact factor: 25.391

7.  Risk of AIDS after herpes zoster.

Authors:  M Melbye; R J Grossman; J J Goedert; M E Eyster; R J Biggar
Journal:  Lancet       Date:  1987-03-28       Impact factor: 79.321

8.  The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.

Authors:  D D Richman; M A Fischl; M H Grieco; M S Gottlieb; P A Volberding; O L Laskin; J M Leedom; J E Groopman; D Mildvan; M S Hirsch
Journal:  N Engl J Med       Date:  1987-07-23       Impact factor: 91.245

9.  The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.

Authors:  M A Fischl; D D Richman; M H Grieco; M S Gottlieb; P A Volberding; O L Laskin; J M Leedom; J E Groopman; D Mildvan; R T Schooley
Journal:  N Engl J Med       Date:  1987-07-23       Impact factor: 91.245

10.  Patients at risk for AIDS-related opportunistic infections. Clinical manifestations and impaired gamma interferon production.

Authors:  H W Murray; J K Hillman; B Y Rubin; C D Kelly; J L Jacobs; L W Tyler; D M Donelly; S M Carriero; J H Godbold; R B Roberts
Journal:  N Engl J Med       Date:  1985-12-12       Impact factor: 91.245

View more
  4 in total

1.  Western immunoblot and flagellum enzyme-linked immunosorbent assay for serodiagnosis of Lyme borreliosis.

Authors:  M Karlsson
Journal:  J Clin Microbiol       Date:  1990-09       Impact factor: 5.948

2.  Quantitation of antibody reactivity to human immunodeficiency virus (type 1) proteins and glycoproteins on Western immunoblots by reflectance densitometry.

Authors:  C T Hardy; T A Damrow; G E Kenny
Journal:  J Clin Microbiol       Date:  1990-11       Impact factor: 5.948

3.  Expression of feline immunodeficiency virus gag gene in Escherichia coli.

Authors:  T Furuya; A Hasegawa; M Saitoh; T Miyazawa; Y Tohya; M Hayami; E Takahashi; K Miki; T Mikami
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

4.  A defined methodology for reliable quantification of Western blot data.

Authors:  Sean C Taylor; Thomas Berkelman; Geetha Yadav; Matt Hammond
Journal:  Mol Biotechnol       Date:  2013-11       Impact factor: 2.695

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.